Does the media favor TBPH or KROS?

In the previous week, Theravance Biopharma had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Theravance Biopharma and 2 mentions for Keros Therapeutics. Theravance Biopharma's average media sentiment score of 0.62 beat Keros Therapeutics' score of 0.51 indicating that Theravance Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Theravance Biopharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AMPH or KROS?

In the previous week, Amphastar Pharmaceuticals and Amphastar Pharmaceuticals both had 2 articles in the media. Amphastar Pharmaceuticals' average media sentiment score of 0.85 beat Keros Therapeutics' score of 0.51 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DSGN or KROS?

In the previous week, Design Therapeutics and Design Therapeutics both had 2 articles in the media. Design Therapeutics' average media sentiment score of 0.54 beat Keros Therapeutics' score of 0.51 indicating that Design Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Design Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, CYRX or KROS?

Keros Therapeutics has higher revenue and earnings than CryoPort. Keros Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CryoPort $182.94M 4.33 $78.30M $1.35 11.64 Keros Therapeutics $244.06M 0.86 $87.01M -$3.01 N/A

Does the media refer more to CYRX or KROS?

In the previous week, CryoPort and CryoPort both had 2 articles in the media. CryoPort's average media sentiment score of 0.84 beat Keros Therapeutics' score of 0.51 indicating that CryoPort is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CryoPort 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Keros Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, GLAS or KROS?

Keros Therapeutics has higher revenue and earnings than Glass House Brands. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glass House Brands $176.02M 4.87 N/A N/A N/A Keros Therapeutics $244.06M 0.86 $87.01M -$3.01 N/A

Does the media favor GLAS or KROS?

In the previous week, Glass House Brands and Glass House Brands both had 2 articles in the media. Keros Therapeutics' average media sentiment score of 0.51 beat Glass House Brands' score of 0.33 indicating that Keros Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glass House Brands 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Keros Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Keros Therapeutics (KROS) Competitors

$10.61 -0.03 (-0.28%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$10.60 -0.01 (-0.09%)

As of 07/20/2026 07:34 PM Eastern

Compare

KROS vs. TBPH, AMPH, DSGN, CYRX, and GLAS

Should you buy Keros Therapeutics stock or one of its competitors? MarketBeat compares Keros Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Keros Therapeutics include Theravance Biopharma (TBPH), Amphastar Pharmaceuticals (AMPH), Design Therapeutics (DSGN), CryoPort (CYRX), and Glass House Brands (GLAS). These companies are all part of the "pharmaceutical products" industry.

How does Keros Therapeutics compare to Theravance Biopharma?

Theravance Biopharma (NASDAQ:TBPH) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, media sentiment and analyst recommendations.

Theravance Biopharma presently has a consensus price target of $19.40, suggesting a potential upside of 15.41%. Keros Therapeutics has a consensus price target of $20.40, suggesting a potential upside of 92.27%. Given Keros Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than Theravance Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Theravance Biopharma had 1 more articles in the media than Keros Therapeutics. MarketBeat recorded 3 mentions for Theravance Biopharma and 2 mentions for Keros Therapeutics. Theravance Biopharma's average media sentiment score of 0.62 beat Keros Therapeutics' score of 0.51 indicating that Theravance Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Theravance Biopharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Theravance Biopharma has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Theravance Biopharma has higher earnings, but lower revenue than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Theravance Biopharma	$109.78M	7.89	$105.89M	$2.20	7.64
Keros Therapeutics	$244.06M	0.86	$87.01M	-$3.01	N/A

Theravance Biopharma has a net margin of 104.34% compared to Keros Therapeutics' net margin of -256.60%. Theravance Biopharma's return on equity of 18.84% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	104.34%	18.84%	10.94%
Keros Therapeutics	-256.60%	-17.04%	-15.84%

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 7.7% of Theravance Biopharma shares are held by insiders. Comparatively, 12.6% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Theravance Biopharma beats Keros Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Keros Therapeutics compare to Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals (NASDAQ:AMPH) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

Amphastar Pharmaceuticals has higher revenue and earnings than Keros Therapeutics. Keros Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amphastar Pharmaceuticals	$719.89M	1.20	$98.09M	$1.66	11.83
Keros Therapeutics	$244.06M	0.86	$87.01M	-$3.01	N/A

In the previous week, Amphastar Pharmaceuticals and Amphastar Pharmaceuticals both had 2 articles in the media. Amphastar Pharmaceuticals' average media sentiment score of 0.85 beat Keros Therapeutics' score of 0.51 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amphastar Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 29.6% of Amphastar Pharmaceuticals shares are owned by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Amphastar Pharmaceuticals presently has a consensus price target of $22.00, indicating a potential upside of 12.07%. Keros Therapeutics has a consensus price target of $20.40, indicating a potential upside of 92.27%. Given Keros Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Keros Therapeutics is more favorable than Amphastar Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amphastar Pharmaceuticals	3 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.63
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Amphastar Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

Amphastar Pharmaceuticals has a net margin of 11.00% compared to Keros Therapeutics' net margin of -256.60%. Amphastar Pharmaceuticals' return on equity of 15.12% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amphastar Pharmaceuticals	11.00%	15.12%	7.14%
Keros Therapeutics	-256.60%	-17.04%	-15.84%

Summary

Amphastar Pharmaceuticals beats Keros Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Keros Therapeutics compare to Design Therapeutics?

Design Therapeutics (NASDAQ:DSGN) and Keros Therapeutics (NASDAQ:KROS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Keros Therapeutics has higher revenue and earnings than Design Therapeutics. Design Therapeutics is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Design Therapeutics	N/A	N/A	-$69.79M	-$1.20	N/A
Keros Therapeutics	$244.06M	0.86	$87.01M	-$3.01	N/A

Design Therapeutics has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Keros Therapeutics' return on equity of -17.04% beat Design Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Design Therapeutics	N/A	-33.07%	-31.29%
Keros Therapeutics	-256.60%	-17.04%	-15.84%

Design Therapeutics has a beta of 1.58, suggesting that its stock price is 58% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

56.6% of Design Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are held by institutional investors. 17.1% of Design Therapeutics shares are held by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Design Therapeutics presently has a consensus price target of $16.50, indicating a potential upside of 39.01%. Keros Therapeutics has a consensus price target of $20.40, indicating a potential upside of 92.27%. Given Keros Therapeutics' higher possible upside, analysts clearly believe Keros Therapeutics is more favorable than Design Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Design Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Design Therapeutics and Design Therapeutics both had 2 articles in the media. Design Therapeutics' average media sentiment score of 0.54 beat Keros Therapeutics' score of 0.51 indicating that Design Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Design Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Design Therapeutics beats Keros Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Keros Therapeutics compare to CryoPort?

CryoPort (NASDAQ:CYRX) and Keros Therapeutics (NASDAQ:KROS) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

CryoPort has a beta of 1.88, indicating that its stock price is 88% more volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

CryoPort presently has a consensus target price of $15.11, indicating a potential downside of 3.81%. Keros Therapeutics has a consensus target price of $20.40, indicating a potential upside of 92.27%. Given Keros Therapeutics' higher probable upside, analysts clearly believe Keros Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

CryoPort has a net margin of 41.57% compared to Keros Therapeutics' net margin of -256.60%. CryoPort's return on equity of -7.92% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CryoPort	41.57%	-7.92%	-4.79%
Keros Therapeutics	-256.60%	-17.04%	-15.84%

Keros Therapeutics has higher revenue and earnings than CryoPort. Keros Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoPort	$182.94M	4.33	$78.30M	$1.35	11.64
Keros Therapeutics	$244.06M	0.86	$87.01M	-$3.01	N/A

In the previous week, CryoPort and CryoPort both had 2 articles in the media. CryoPort's average media sentiment score of 0.84 beat Keros Therapeutics' score of 0.51 indicating that CryoPort is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CryoPort	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of CryoPort shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 9.5% of CryoPort shares are owned by company insiders. Comparatively, 12.6% of Keros Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

CryoPort beats Keros Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Keros Therapeutics compare to Glass House Brands?

Glass House Brands (NYSE:GLAS) and Keros Therapeutics (NASDAQ:KROS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

71.6% of Keros Therapeutics shares are held by institutional investors. 12.6% of Keros Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Glass House Brands has a net margin of 0.00% compared to Keros Therapeutics' net margin of -256.60%. Glass House Brands' return on equity of 0.00% beat Keros Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glass House Brands	N/A	N/A	N/A
Keros Therapeutics	-256.60%	-17.04%	-15.84%

Keros Therapeutics has higher revenue and earnings than Glass House Brands.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glass House Brands	$176.02M	4.87	N/A	N/A	N/A
Keros Therapeutics	$244.06M	0.86	$87.01M	-$3.01	N/A

Glass House Brands currently has a consensus target price of $17.00, indicating a potential upside of 59.27%. Keros Therapeutics has a consensus target price of $20.40, indicating a potential upside of 92.27%. Given Keros Therapeutics' higher probable upside, analysts plainly believe Keros Therapeutics is more favorable than Glass House Brands.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glass House Brands	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Glass House Brands and Glass House Brands both had 2 articles in the media. Keros Therapeutics' average media sentiment score of 0.51 beat Glass House Brands' score of 0.33 indicating that Keros Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glass House Brands	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Keros Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Glass House Brands and Keros Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get Keros Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KROS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KROS vs. The Competition

Export

Metric	Keros Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$210.59M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-3.52	20.49	27.07	23.94
Price / Sales	0.86	300.33	512.71	90.33
Price / Cash	2.35	60.31	26.68	47.25
Price / Book	0.68	7.92	10.63	6.14
Net Income	$87.01M	$23.81M	$3.60B	$331.74M
7 Day Performance	0.38%	-1.09%	-1.24%	-1.82%
1 Month Performance	-0.70%	2.56%	1.09%	-1.45%
1 Year Performance	-23.06%	42.16%	23.66%	16.32%

Keros Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KROS Keros Therapeutics	3.198 of 5 stars	$10.61 -0.3%	$20.40 +92.3%	-22.8%	$210.59M	$244.06M	N/A	100
TBPH Theravance Biopharma	2.9529 of 5 stars	$16.97 +0.2%	$19.40 +14.3%	+49.4%	$872.79M	$107.46M	7.71	110
AMPH Amphastar Pharmaceuticals	3.2197 of 5 stars	$19.86 +2.4%	$22.00 +10.8%	-4.8%	$855.40M	$719.89M	11.96	1,976
DSGN Design Therapeutics	2.1585 of 5 stars	$12.61 -6.7%	$16.50 +30.8%	+198.2%	$844.42M	N/A	N/A	40
CYRX CryoPort	3.1316 of 5 stars	$16.49 -0.5%	$15.11 -8.4%	+118.5%	$835.17M	$176.18M	12.21	1,186	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KROS) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Keros Therapeutics (KROS) Competitors

KROS vs. TBPH, AMPH, DSGN, CYRX, and GLAS

How does Keros Therapeutics compare to Theravance Biopharma?

Summary

How does Keros Therapeutics compare to Amphastar Pharmaceuticals?

Summary

How does Keros Therapeutics compare to Design Therapeutics?

Summary

How does Keros Therapeutics compare to CryoPort?

Summary

How does Keros Therapeutics compare to Glass House Brands?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Keros Therapeutics (KROS) Competitors

KROS vs. TBPH, AMPH, DSGN, CYRX, and GLAS

How does Keros Therapeutics compare to Theravance Biopharma?

Do analysts prefer TBPH or KROS?

Does the media favor TBPH or KROS?

Which has more volatility & risk, TBPH or KROS?

Which has stronger earnings & valuation, TBPH or KROS?

Is TBPH or KROS more profitable?

Do insiders and institutionals have more ownership in TBPH or KROS?

Summary

How does Keros Therapeutics compare to Amphastar Pharmaceuticals?

Which has preferable earnings & valuation, AMPH or KROS?

Does the media favor AMPH or KROS?

Do insiders & institutionals have more ownership in AMPH or KROS?

Do analysts rate AMPH or KROS?

Which has more risk and volatility, AMPH or KROS?

Is AMPH or KROS more profitable?

Summary

How does Keros Therapeutics compare to Design Therapeutics?

Which has stronger earnings & valuation, DSGN or KROS?

Is DSGN or KROS more profitable?

Which has more volatility and risk, DSGN or KROS?

Do institutionals & insiders have more ownership in DSGN or KROS?

Do analysts prefer DSGN or KROS?

Does the media favor DSGN or KROS?

Summary

How does Keros Therapeutics compare to CryoPort?

Which has more risk and volatility, CYRX or KROS?

Do analysts recommend CYRX or KROS?

Is CYRX or KROS more profitable?

Which has higher earnings & valuation, CYRX or KROS?

Does the media refer more to CYRX or KROS?

Do insiders & institutionals have more ownership in CYRX or KROS?

Summary

How does Keros Therapeutics compare to Glass House Brands?

Do insiders & institutionals have more ownership in GLAS or KROS?

Is GLAS or KROS more profitable?

Which has preferable valuation & earnings, GLAS or KROS?

Do analysts recommend GLAS or KROS?

Does the media favor GLAS or KROS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KROS vs. The Competition

Keros Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools